Logo Prima Biomed


Welcome to the Newsroom

15 March 2016

IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal


ENGLISH

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using IMP321 as an adjuvant to a therapeutic vaccine has been published in the March 15 edition of the Clinical Cancer Research journal. The paper is titled "Vaccination with sLAG-3-Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients: report of a phase I/IIa clinical trial" and is the result of a long-standing academic collaboration between Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Chief Medical Officer and scientists at the Ludwig Centre for Cancer Research at the University of Lausanne, Switzerland.

 (...)